Joseph M. McNamara, MD

Associate Professor of Pediatrics (Hematology / Oncology)

Patient Care

Accepts new patients? Yes
Patient Type: Adolescent; Child
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Pediatric Hematology & Oncology Program

Pediatrics: Pediatric Hematology & Oncology

Yale Medical Group

Board Certifications

  • Pediatric Hematology-Oncology AB of Pediatrics (1990)

Clinical Trials

Conditions Study Title
Brain and Nervous System LGG-14C03 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Brain and Nervous System ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Non-Hodgkin's Lymphoma ANHL12P1 A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117.A Groupwide Phase II Study (Limited to US sites)
Hodgkin's Lymphoma AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in children and Adolescents A Groupwide Phase III Study (Limited to US and Canada sites) THIS
Hodgkin's Lymphoma AHOD1221 - A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Soft Tissue ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) An Intergroup NCTN Phase II/III Study
Brain and Nervous System ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma A Groupwide Historically Controlled Phase III Study
Brain and Nervous System ACNS1221: A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Bones and Joints AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Lymphoid Leukemia AALL1231 -- A Phase III Randomized Trial Investigating Bortezomib (NSC#681239; IND#58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL_ and T-Lymphoblastic Lymphoma (T-LLy) -- A Groupwide Phase III Study
Eye and Orbit ARET12P1 A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma: A Limited Institution Pilot Study
Other Respiratory and Intrathoracic Organs ALTE11C2: Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Preventionof Anthracycline-related Cardiomyopathy
Other Hematopoietic ACCL1034 Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Soft Tissue ANBL1221 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, IND#61010) or Chimeric 14.18 Antibody (ch 14.18) (NSC#623408, IND#4308) in Children with Refractory or Progressive Neuroblastoma
Leukemia, other ANHL1131 Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of Rituximab efficacy and safety in high risk patients
Myeloid and Monocytic Leukemia AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for patients with High Allelic Ratio FLT3/ITD; A Groupwide II/III Study
Unknown Sites Genetic Aspects of Familial Malignancies
Ill-Defined Sites Umbrella Long-Term Follow-Up Protocol (COG ALTE05N1) (CIRB)
Lymphoid Leukemia Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer (COG ALTE07C1) (CIRB)
Unknown Sites Key Adverse Events after Childhood Cancer (COG ALTE03N1)

Edit this profile

Contact Info

Joseph M. McNamara, MD
Patient Care Location
Yale Pediatric Hematology & OncologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 7th floor

New Haven, CT 06511
Mailing Address
PO Box 208064
New Haven, CT 06520-8064